Scott Biller

Scott Biller is currently an executive venture partner at GV and also serves as an independent board member and advisor for several biotechs. Scott retired as CSO of Agios Pharmaceuticals at the end of 2019, a position he held for over 9 years. As CSO, Dr. Biller led the efforts to discover three approved medicines: TIBSOVO and IDHIFA, for acute myeloid leukemia harboring IDH1 and IDH2 mutations, respectively, and PYRUKYND for pyruvate kinase deficiency. Prior to Agios, Dr. Biller held various R&D leadership roles at Novartis and BMS. At BMS, his research focused in the metabolic diseases area, where teams under his leadership discovered multiple investigational medicines and three marketed drugs: the DPP4 inhibitor ONGLYZA® for Type 2 diabetes, the SGLT2 inhibitor FARXIGA® for Type 2 diabetes and the MTP inhibitor JUXTAPID® for familial hypercholesterolemia. Dr. Biller was awarded a B.S. in chemistry from MIT, a Ph.D. in organic chemistry from Caltech and an NIH Postdoctoral Fellowship at Columbia University.